NCT01448707View on ClinicalTrials.gov

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

March 15, 2012

Primary Completion Date

June 11, 2014

Study Completion Date

March 18, 2015

Conditions
Human Immunodeficiency Virus (HIV) InfectionsAcquired Immunodeficiency Syndrome (AIDS) Virus
Interventions
DRUG

Darunavir

Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use

DRUG

Ritonavir

ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use

Trial Locations (34)

Unknown

Graz

Vienna

Antwerp

Brussels

Ghent

Copenhagen

Hvidovre

Bobigny

Bondy

Dijon

Paris

Berlin

Bonn

Cologne

Frankfurt

Hanover

Budapest

Dublin

Galway

Beersheba

Ramat Gan

Tel Aviv

Warsaw

Badalona

Barcelona

Córdoba

Granada

Madrid

Stockholm

Sankt Gallen

Zurich

Brighton

London

Manchester

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY

NCT01448707 - A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment | Biotech Hunter | Biotech Hunter